Clinical trials: Patients With ST-elevated Myocardial Infarction
- Condition Patients With ST-elevated Myocardial Infarction
- Funder type Industry (pharma, biotech, devices)
STEMI, Dyslipidemias
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor…
- Trial name
- NCT05579418
- Testing
- Evolocumab
- Volunteers
- 350 people
- Sponsor
- Hamad Medical Corporation
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
ST Elevation Myocardial Infarction
Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI)…
- Trial name
- NCT03991143
- Testing
- ATH3G10
- Where
- Sweden
- Volunteers
- 82 people
- Sponsor
- Athera Biotechnologies AB
ST Elevation (STEMI) Myocardial Infarction
PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention
A prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ECG changes (ST segment elevation) receive angioplasty followed by stent placement and 90 minutes of…
- Trial name
- pRAMSES (NCT01493037)
- Testing
- PICSO (Pressure-controlled Intermittent Coronary Occlusion
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Miracor Medical SA
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Focus of Study is STEMI
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.
- Trial name
- NCT01977755
- Testing
- danegaptide
- Where
- Denmark
- Volunteers
- 591 people
- Sponsor
- Zealand Pharma
ST Segment Elevated Myocardial Infarction
OCT Study of the MGuard Prime Stent in Patients With Heart Attacks
The objective is to demonstrate that the Flow Area within a blocked coronary vessel as assessed by OCT is greater with the MGuard Prime stent compared to non-mesh control stent (BMS/DES) in subjects undergoing primary PCI for…
- Trial name
- MASTER-OCT (NCT02222116)
- Testing
- MGuard Prime, Control BMS DES
- Where
- United Kingdom
- Sponsor
- InspireMD
STEMI - ST Elevation Myocardial Infarction
Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute STEMI After Primary PCI
To evaluate the influence of Salvianolate injection on myocardial microcirculation perfusion in subjects with STEMI who underwent primary PCI
- Trial name
- SISTEMI (NCT03045562)
- Testing
- Normal saline, Salvianolate injection
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Green Valley Group of China
Cardiogenic Shock, STEMI
Incorporating Supersaturated Oxygen in Shock
A multi-center, prospective randomized (1:1) pilot and feasibility study to evaluate the safety and feasibility of supersaturated oxygen (SSO2) therapy delivered for 60 minutes selectively into the culprit coronary artery of…
- Trial name
- ISO-SHOCK (NCT04876040)
- Testing
- SSO2 Downstream System, PCI + Impella
- Where
- 7 sites in United States
- Sponsor
- TherOx
ST Elevation Myocardial Infarction
MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction
Prospective, non-randomized, single arm, multicenter observational study. The objective is to evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of de novo stenotic lesions in coronary arteries in…
- Trial name
- e-MASTER (NCT02292823)
- Testing
- MGuard™ Prime Embolic Protection Stent System
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- InspireMD
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Thromboembolism
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of…
- Trial name
- NCT00064428
- Testing
- fondaparinux - UFH not indicated, Control - UFH not indicated, Fondaparinux - UFH indicated
- Volunteers
- 12,092 people
- Sponsor
- GlaxoSmithKline
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Sweden Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667003
- Where
- 8 sites in Sweden
- Volunteers
- 406 people
- Sponsor
- Biotronik ApS
Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
The goal of this phase IIc clinical trial is to learn if recombinant human thymosin beta 4 injection (NL005) works to treat heart damage in people who have had a serious type of heart attack called ST-segment elevation myocardial…
- Conditions
- Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall, Acute Myocardial Infarction With ST Elevation, Acute Myocardial Infarction of Left Ventricle
- Trial name
- NCT07586865
- Testing
- Recombinant Human Thymosin Beta 4 Injection (NL005)
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Coronary Disease, Myocardial Infarction
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous administration.
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Diseases, Vascular Diseases
- Trial name
- CEL-02 (NCT04284995)
- Testing
- RUC-4 Compound
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- CeleCor Therapeutics
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Coronary Artery Disease, Coronary Syndrome
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable Angina
The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at…
- Conditions
- Coronary Artery Disease, Coronary Syndrome, Cryotherapy Effect, Myocardial Infarction
- Trial name
- POLARSTAR (NCT05600088)
- Testing
- CryoTherapy System (CTS)
- Where
- 5 sites in Georgia, Lithuania
- Volunteers
- 30 people
- Sponsor
- Cryotherapeutics SA
Acute Coronary Syndrome
VitalScan MCG Rule-out Multi-centre Pivotal Study - UK
The study is a prospective multi-centre observational study to evaluate a portable magnetocardiograph device for the rule-out of acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain…
- Trial name
- MAGNET-ACS (NCT02921438)
- Testing
- VitalScan Magnetocardiograph
- Where
- 5 sites in United Kingdom
- Volunteers
- 756 people
- Sponsor
- Creavo Medical Technologies Ltd
Non-ST Elevation Myocardial Infarction (NSTEMI)
Prevention of Acute Kidney Injury in Patients With NSTEMI
A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography.
- Trial name
- AKI (NCT04912141)
- Where
- 4 sites in Switzerland
- Volunteers
- 29 people
- Sponsor
- Pharming Technologies B.V.